AU2003266086A1 - Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine) - Google Patents

Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)

Info

Publication number
AU2003266086A1
AU2003266086A1 AU2003266086A AU2003266086A AU2003266086A1 AU 2003266086 A1 AU2003266086 A1 AU 2003266086A1 AU 2003266086 A AU2003266086 A AU 2003266086A AU 2003266086 A AU2003266086 A AU 2003266086A AU 2003266086 A1 AU2003266086 A1 AU 2003266086A1
Authority
AU
Australia
Prior art keywords
cytokine
lymphocytic leukemia
chronic lymphocytic
combination treatment
cll cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003266086A
Inventor
David E. Spaner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU2003266086A1 publication Critical patent/AU2003266086A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003266086A 2002-09-16 2003-09-15 Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine) Abandoned AU2003266086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41120402P 2002-09-16 2002-09-16
US60/411,204 2002-09-16
PCT/CA2003/001408 WO2004024171A1 (en) 2002-09-16 2003-09-15 Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)

Publications (1)

Publication Number Publication Date
AU2003266086A1 true AU2003266086A1 (en) 2004-04-30

Family

ID=31994247

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003266086A Abandoned AU2003266086A1 (en) 2002-09-16 2003-09-15 Chronic lymphocytic leukemia combination treatment (treated cll cells and cytokine)

Country Status (2)

Country Link
AU (1) AU2003266086A1 (en)
WO (1) WO2004024171A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653020B1 (en) * 1989-10-17 1993-03-26 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
CA2324199A1 (en) * 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment

Also Published As

Publication number Publication date
WO2004024171A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
AU2003227235A1 (en) Treating device, electrode, electrode plate, and treating method
AU2003213768A1 (en) Use of benzimidazole analogs in the treatment of cell proliferation
AU2003254689A1 (en) Table, especially conference and office table
AU2003254688A1 (en) Table, especially office and conference table
AU2003233713A1 (en) Systems and methods for channel allocation for forward-link in multi-user systems
IL174796A0 (en) Methods for treating viral infection using-il-28 and il-29
AU2003229027A1 (en) Hydrocarbon-terminated polyether-polyamide block copolymers and uses thereof
AU2003220598A1 (en) Fluid-assisted medical devices, systems and methods
AU2003239473A1 (en) Fluid-assisted medical devices, systems and methods
AU2003267255A1 (en) Methods and devices for active bioassay
AU2003285447A1 (en) Transparent polyamide block and polyether block copolymers
AU2003206012A1 (en) Rate allocation and control for multicast services in wireless networks
AU2003214393A1 (en) Water filter and treatment system and component
AU2003286945A1 (en) Plasma reactor and electrode plate used in the same
AU2003285139A1 (en) Heat treated high density structures
EP1510819A4 (en) Bioassay unit and substrate for bioassay
AU2002359947A1 (en) Substrate treatment apparatus
AU2003268032A1 (en) Composition and methods for treatment and screening
AU2002332224A1 (en) Arrangement and method for electrochemical purification or treatment
AU2003257620A1 (en) Substrate treating apparatus
AU2002338191A1 (en) Surface treatment system and surface treatment method
AU2002258857A1 (en) Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
AU2002318711A1 (en) Controllable released suppository used in milk-secreting channel
AU2003227987A1 (en) Machining apparatus and methods
AU2003268376A1 (en) Transdermal delivery systems and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase